Crescendo Biologics is focusing on novel T cell enhancing therapeutics in immuno-oncology.

Crescendo Biologics (Crescendo) is focused on transforming the lives of cancer patients through its pipeline of novel T cell enhancing therapies. The lead programme, CB307, is a first in class CD137 (4-1BB) x PSMA bispecific molecule. Behind the lead programme is a pipeline of other first or best in class CD137 (4-1BB) bispecifics for solid tumours.

T cell enhancing pipeline advantages:

  • Enhanced safety via conditional activation of tumour-specific T cells in the tumour micro-environment
  • Proliferation of tumour-specific T cells to enhance tumour cell killing
  • Survival of tumour-specific T cells for a more durable anti-cancer effect (‘memory’ responses)

Crescendo’s pipeline is underpinned by its proprietary Humabody® VH platform. This platform is based on its transgenic mouse, from which are derived fully human VH domains. These VH domains can be used on their own or can be combined with other VH domains to create multi-functional molecules with unique properties designed to overcome some of the limitations of traditional IgG-based molecules.

Crescendo Biologics enters pre-clinical collaboration with Orano Med to explore Targeted Alpha Therapy

Crescendo Biologics enters pre-clinical collaboration with Orano Med to explore Targeted Alpha Therapy

View PDF

Crescendo Biologics and Cancer Research UK sign Clinical Development Partnership to develop CB213, a novel bispecific Humabody® therapeutic

Crescendo Biologics and Cancer Research UK sign Clinical Development Partnership to develop CB213, a novel bispecific Humabody® therapeutic

View PDF

Patent-protected transgenic VH platform facilitates rapid assembly of optimally configured Humabody®  therapeutics for novel biology.